Windows LiveWindows Live™

Lapatinib 

_phase1 safety, pharmacokinetics, and clinical activity study of lapatinib, a reversible dual inhibitor of epidermal growth factor receptor
_Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor andor erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors
_Study of the Biologic Effects of Lapatinib, a Reversible
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
A Multiscale Computational Approach to Dissect Early Events in the Erb Family Receptor Mediated Activation, Differential Signaling and Relevance to Oncogenic Transformations
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (lapatinib)
Activity of Dual Kinase inhibitor lapatinib against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer cells
Biology of Interactions - Antiepidermal Growth Factor receptor agents
Breakthrough for neoadjuvant chemotherapy
Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling
Changes in the treatment of breast cancer
Chemoprevention of breast cancer
Clinical Advancement of EGFR Inhibitors in Cancer Therapy
Clinical trials of intracellular signal transductions inhibitors for breast cancer — a strategy to overcome endocrine resistance
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs- a model for treatment
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells
Combining targeted therapies
Considerations in treatment choice for metastatic breast cancer
Current Therapeutic Options for Breast Cancer Central Nervous System Metastases
Development of new targeted therapies for breast cancer
Dual Kinase inhibition in the treatment of breast cancer
DUAL PAN-HER TYROSINE KINASE INHIBITORS - FOCUS IN BREAST CANCER
Effect of Food on lapatinib pharmacokinetics
Emerging therapeutic options for breast cancer chemotherapy during pregnancy
Endocrine and targeted treatments for breast cancer
Epidermal growth factor receptor(EGFR) inhibitors in cancer therapy
ErbB Protein Tyrosine Kinases
Evaluation of the current knowledge limitations in breast cancer research
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer
HER-2 neu diagnostics in breast cancer
impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib
Inhibition of Growth Factor Signaling
Issues and controversies in the treatment of HER2 positive metastatic breast cancer
Lapatinib
lapatinib - Associated toxicity and practical management recommendations
lapatinib antitumor activity is not dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast Cancers
Lapatinib for HER2-Positive Breast Cancer Patients
lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells
Lapatinib Moves Forward in Inflammatory and Early HER2-Positive Breast Cancer Trials
lapatinib plus capecitabine
Lapatinib-a novel dual tyrosine kinase inhibitor
lapatinib-Current Status and Future directions in breast cancer
Molecular mechanisms of trastuzumab resistance
new insight into estrogen receptor alpha function and its implication for endocrine therapy resistance in breast cancer
Overcoming endocrine resistance in breast cancer—are signal transduction inhibitors the answer
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
Pharmacodynamics- biological activity of targeted therapies in clinical trials
Phase1 and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies
Phase1 pharmacokinetic study of the safety and tolerability of lapatinib in combination with oxaliplatin,Fluorouracil,leucovorin in patients with solid tumors
phase I_EGF10001
phase I_EGF10002
phase I_EGF10003
phase I_EGF10004
phase I_EGF10005
phase I_EGF10008
phase I_EGF10009
phase I_EGF10010
phase I_EGF10011
phase I_EGF10012
phase I_EGF10013
phase I_EGF10014
phase I_EGF10015
phase I_EGF10018
phase I_EGF10019
phase I_EGF10021
phase I_EGF10023
phase I_EGF10024
phase I_EGF10030
phase I_EGF10032
phase I_EGF100262
phase I_EGF102587
Phase II Study of Predictive Biomarker Profiles for Response
phase II_EGF20002
phase II_EGF20003
phase II_EGF20004
phase II_EGF20008
phase II_EGF20009
phase II_EGF20014
phase II_EGF102580
phase II_EGF102980
phase III_EGF20001
phase III_EGF100151
phase III_EGF100151_cut
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
Predictive Pathology of Cytostatic Drug Resistance and New Anti-cancer Targets
Principles of Targeted and biological therapies
Protein Tyrosine Kinases as Cancer Targets
Protein Tyrosine Kinases as Targets for cancer and other indications
Regulation of Survivin by ErbB2 Signaling - Therapeutic Implications for ErbB2-Overexpressing Breast Cancers
Small molecule HER-2 tyrosine kinase inhibitors
Small Molecule Tyrosine Kinase Inhibitors in the Treatment of solid tumors
Small-Molecule Receptor Tyrosine Kinase Inhibitors in Targeted Cancer Therapy
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
Targeted Therapy for Metastatic Breast Cancer
TARGETING SMALL MOLECULES IN CANCER
Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer
The dual EebB1-ErbB2 inhibitor, lapatinib, cooperates with tamoxifen to inhibit both cell proliferation- and Estrogen- dependent gene expression in antiestrogen-resistant breast cancer
The Emerging Role of Lapatinib in her2-positive breast cancer
The ErbB2 Signaling Network as a Target for breast cancer therapy
The Role of the Epidermal Growth Factor Receptor in breast cancer
The Value Meal - Effect of Food on lapatinib bioavailability
The Value Meal - How to Save 1,700 Per Month or more on lapatinib
The Value of Label Recommendations - how to dose lapatinib
Therapeutic aspect of metastatic breast cancer-chemotherapy
To overcome breast cancer with all of our knowledge
tyrosine_kinase_receptor
UPDATE ON THE ROLE OF EGFR INHIBITORS IN CANCER THERAPEUTICS
web
บทนำ_
หัวข้อรายงาน
หัวข้อรายงาน lapatinib
Shared with: Everyone (public)